Maraviroc and Rifampicin (Rifcap 300 mg Kapsül): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
CYP3A induction can reduce maraviroc exposure and antiviral activity.
Clinical significance and safety
Rifcap 300 mg capsule can lower maraviroc exposure through CYP3A induction, potentially reducing HIV control. Management differs if a strong CYP3A inhibitor is also present, so specialist review of the entire regimen is essential. The cited U.S. label contraindicates potent-inducer combinations in severe renal impairment or end-stage renal disease.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.